Skip to Content Facebook Feature Image

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

Business

Best Poster of ESMO  2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
Business

Business

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

2024-09-19 09:00 Last Updated At:09:15

SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study". The update data from ABSK-011-101 study showed a tolerable safety profile and promising anti-tumor activity of Irpagratinib monotherapy in aHCC. Of note, in aHCC patients who were pretreated with both immune checkpoint inhibitor (ICI) and Tyrosine Kinase Inhibitor (TKI)—a population with high unmet need in the current treatment paradigm—the observed ORR and DCR was 44.8% and 79.3%, respectively, with a median duration of response (mDoR) of 7.4 months and median progression free survival (mPFS) of 5.5 months.

The poster, #983P, was presented at the Hepatocellular Carcinoma poster session on Sunday, September 16, 2024. The Best Poster Award was given at the conclusion of the Sunday Poster Session, with only one recipient being honored in HCC poster session.

As of September 5, 2024, 122 patients have been enrolled, including 74 in the BID cohort with doses consisting of 160mg BID, 220mg BID, and 300mg BID. 5.4% of patients were BCLC Stage B, and 89.2% BCLC Stage C, 64.9% had a Child-Pugh (CP) Score of 5, 27% CP Score of 6, and 6.8% CP Score of 7. 64.9% of patients received multiple lines of prior therapy, 85.1% of patients had previously been treated with ICIs, and 75.7% of patients had previously been treated with both ICIs and mTKIs.

The efficacy data show that forty pre-treated HCC patients with FGF19 overexpression were treated with irpagratinib 220 mg BID. Among the 38 evaluable patients, the response rate was 36.8% (14/38), and the disease control rate (DCR) was 78.9% (30/38). The response rate from the subset of patients who had previously received ICI and mTKI therapy was 44.8% (13/29). The longest observed DoR was 16.4 months and the mDoR was 7.4 months. DCR was 79.3% (23/29). mPFS was 5.5 months.

Safety data show one dose-limiting toxicity (DLT) was observed in the 300 mg BID cohort. The most common treatment-related adverse effects (TRAEs, >20%) were ALT elevation, diarrhea, AST elevation, hyperphosphatemia, bilirubin elevation, alkaline phosphatase elevation, platelet decrease, and total bile acid elevation. Grade 3-4 treatment-related adverse events (>5%) included AST elevation, ALT elevation, and diarrhea. No grade 5 adverse events occurred.

HCC is the main type of liver cancer, accounting for 85% to 90% of primary liver cancers.  HCC is highly malignant, about 30% of which have abnormally high FGFR4 expression and a poor prognosis, and the existing treatment methods still cannot meet the long-term survival benefits.  Currently, there is no approved standard of care for HCC patients who have progressed from first-line ICI-based therapies. The FGF19/FGFR4 signaling axis could be a novel therapeutic target for HCC. ABSK-011, a potent FGFR4 inhibitor, demonstrated a tolerable safety profile and promising anti-tumor activity as a single agent. Notably, the irpagratinib 220mg BID regimen exhibited a 44.8% ORR, 7.4 months mDoR and 5.5 months mPFS in heavily pre-treated HCC patients who had received both ICI and mTKI therapy, supporting further late-stage development of irpagratinib in such populations with substantial unmet medical need.

In addition, the design of the phase II study of pimicotinib in combination with chemotherapy and with/without toripalimab as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) has been presented.

About Irpagratinib (ABSK011)

Irpagratinib is a highly selective FGFR4 small molecule inhibitor intended for the treatment of advanced solid tumors that present with abnormalities in the FGF19/FGFR4 signaling pathway (e.g., ligand FGF19 amplification/overexpression, FGFR4 mutation/amplification/fusion), including advanced HCC, cholangiocarcinoma, breast cancer, among others. The FGFR4 signaling pathway is a recognized and promising target for treating HCC. Clinical data with irpagratinib have demonstrated improved potency and anti-tumor efficacy, among other favorable therapeutic properties, compared to competitors.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to the discovery and development of innovative medicines that treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology. Please visit www.abbisko.com for more information.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Best Poster of ESMO  2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

HANOI, Vietnam, Nov. 8, 2024 /PRNewswire/ -- DND International Eye Hospital is the first facility in Vietnam to implement SMILE Pro technology, an advanced FDA-approved eye refractive surgery method. It is also an ideal destination for international tourists seeking to combine travel with refractive eye surgery.

Health tourism is rapidly gaining popularity in Asia, and Eye Refractive Surgery in Vietnam is becoming an appealing option for international tourists due to its high-quality medical services and affordability.

Travelers are increasingly seeking not just attractive destinations but also opportunities to improve their health, particularly through medical services like eye refractive surgery. Vietnam is emerging as a prime destination that fulfills both tourism and healthcare needs, with the DND International Eye Hospital in Hanoi being a leading choice for eye refractive surgery.

1. Convenient Solution: Combining Tourism and Eye Refractive Surgery

Many international travelers are opting to combine tourism with myopia surgery to save time and costs. The surgery is safe, quick, and offers a short recovery period, making it ideal during travel.

At DND International Eye Hospital, a pre-surgery eye examination takes about two hours, and the surgery itself lasts only 15-20 minutes. Patients can even complete a comprehensive exam and surgery in a single day. After a 24-hour post-surgery check, they can continue exploring Vietnam's beautiful sights with confidence.

2. Cutting-Edge Technology for Eye Refractive Surgery

Quality equipment and technology are crucial when choosing a place for  lasik surgery. DND International Eye Hospital is equipped with state-of-the-art systems that meet international standards. This includes advanced diagnostic tools and the latest laser machines, such as the VISUMAX 800 laser with SMILE Pro technology and the Femto LDV Z8 from Ziemer, both of which are FDA-certified for safety and effectiveness.

SMILE Pro's 2mm incision quickly corrects refractive errors while minimizing risks and promoting fast recovery. DND leads the Asia-Pacific region in the number of SMILE surgeries, demonstrating its credibility and service quality.

3. Leading Ophthalmologists in Vietnam

DND International Eye Hospital features a highly qualified team of ophthalmologists with over 30 years of experience. These specialists are pioneers in SMILE technology and continually update their skills at international institutions, ensuring that each surgery is performed by experts dedicated to the latest medical advancements.

Additionally, the doctors and staff are proficient in English, facilitating effective communication with international patients. This presence of top specialists and English-speaking personnel builds trust among local and international patients alike. The hospital also offers 24/7 support for patients before and after surgery.

4. Cost-Effective Lasik Eye Surgery

Myopia surgery in Vietnam is attracting international tourists due to its affordability. Compared to countries like the U.S. and Japan, the costs in Vietnam are significantly lower while maintaining comparable quality. For instance, while SMILE surgery costs around $6,000 - $8,000 in the U.S., in Vietnam, it is only about a third of that price.

5. Comprehensive Examination Process for Safety

DND International Eye Hospital prioritizes patient safety with a thorough examination process comprising eight international standard steps. This includes various assessments to ensure safe surgery and optimal outcomes tailored to individual needs.

6. 5-Star Medical Service

DND International Eye Hospital offers a 5-star service experience, featuring a friendly environment and attentive care. Patients are warmly welcomed and guided throughout their treatment, and the hospital provides free periodic post-surgery checkups to ensure ongoing health monitoring.

The health tourism trend, especially in eye refractive surgery, presents numerous opportunities for international visitors to Vietnam. With modern technology, a specialized medical team, and attentive service, DND International Eye Hospital is the perfect choice for those looking to enhance their vision while enjoying a memorable vacation. The hospital guarantees a remarkable healthcare experience at reasonable costs.

For more information about DND International Eye Hospital, please contact:

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam

DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam

Recommended Articles